Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cancer Research

Roche Basel Switzerland

Roche shares slip as profits miss expectations

But shows solid sales growth thanks to its oncology portfolio

EISAI

Eisai’s Lenvima gets FDA priority review for kidney cancer

The oncology treatment could now be approved in the US before the summer

- PMLiVE

Merck & Co buys IOmet to boost immuno-oncology tech

Reports suggest it paid up to £280m for the Scottish biopharma company

Why is the UK lagging behind the rest of Europe in cancer survival?

Say Communications, London healthcare PR agency, discusses the latest technologies that will improve cancer survival rates in UK

Say Communications

- PMLiVE

National Audit Office agrees CDF is ‘unsustainable’

Says a replacement for the CDF is urgently needed

- PMLiVE

Freeman: More pharma-charity research partnerships needed

Life sciences minister wants greater collaboration between organisations

- PMLiVE

AZ opens new research centre with Cancer Research UK

MedImmune partners with CRUK in Cambridge-based R&D hub

ASCO 2015: What you missed in Chicago

Blue Latitude sent two of our consultants to Chicago to attend ASCO 2015, a key annual meeting for oncology specialists that brings over 30,000 delegates together to talk about innovations...

Blue Latitude Health

- PMLiVE

Amgen and Merck to expand cancer collaboration

Firms to test Keytruda in combination for cancers inside the head and neck

- PMLiVE

Rise in cancer therapy costs ‘unsustainable’ says oncologist

Leonard Saltz made the claims in his keynote presentation at ASCO

- PMLiVE

Afinitor set for filing this year in neuroendocrine cancer

Novartis drug is already approved for breast and renal cancers

- PMLiVE

Ipsen acquires OctreoPharm to boost its oncology presence

Will aid the development of its approach to neuroendrocrine tumours

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links